April 8 (Reuters) - Catalyst Pharmaceuticals Inc:
* SEES FY 2020 REVENUE $135 MILLION TO $155 MILLION
* DRUG SUPPLY REMAINS WELL-STOCKED WITH PATIENTS HAVING ACCESS TO UNINTERRUPTED SUPPLY OF FIRDAPSE (AMIFAMPRIDINE) 10MG
* FIRDAPSE SUPPLY CHAIN REMAINS ROBUST AND READY FOR ANY CONTINGENCIES THAT ARISE DUE TO COVID-19 OUTBREAK
* WE HAVE OBSERVED NO DISRUPTIONS IN PRODUCTION OF FIRDAPSE
* CONTINUE TO ASSESS POTENTIAL IMPACT THAT COVID-19 COULD HAVE ON OUR REVENUE
* REPORTED IT HAD $94.5 MILLION OF CASH AND INVESTMENTS AS OF DECEMBER 31, 2019
* AS OF TODAY, CATALYST CONTINUES TO HAVE NO FUNDED DEBT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Our Standards: The Thomson Reuters Trust Principles.